Nexthera Capital LP acquired a new stake in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 41,905 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,701,000.
A number of other hedge funds also recently modified their holdings of ANIP. Bank of Montreal Can boosted its position in ANI Pharmaceuticals by 681.8% during the fourth quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock valued at $156,000 after purchasing an additional 2,100 shares in the last quarter. SG Americas Securities LLC bought a new stake in ANI Pharmaceuticals during the third quarter valued at about $197,000. Violich Capital Management Inc. bought a new stake in ANI Pharmaceuticals during the third quarter valued at about $217,000. Driehaus Capital Management LLC bought a new stake in ANI Pharmaceuticals during the fourth quarter valued at about $220,000. Finally, Crossmark Global Holdings Inc. bought a new stake in ANI Pharmaceuticals during the third quarter valued at about $226,000. 55.95% of the stock is currently owned by institutional investors.
Shares of ANI Pharmaceuticals Inc (ANIP) opened at $62.75 on Tuesday. The company has a quick ratio of 2.39, a current ratio of 3.36 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $733.24, a PE ratio of -627.50 and a beta of 2.75. ANI Pharmaceuticals Inc has a twelve month low of $42.23 and a twelve month high of $74.70.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.06. The business had revenue of $47.30 million during the quarter, compared to the consensus estimate of $52.55 million. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. The company’s quarterly revenue was up 23.8% on a year-over-year basis. During the same quarter last year, the company earned $0.84 earnings per share. sell-side analysts forecast that ANI Pharmaceuticals Inc will post 5.17 EPS for the current year.
A number of brokerages recently weighed in on ANIP. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 25th. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Canaccord Genuity set a $75.00 price objective on ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, December 9th. Zacks Investment Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $72.25.
In other ANI Pharmaceuticals news, SVP James G. Marken sold 4,177 shares of the firm’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $61.92, for a total value of $258,639.84. Following the completion of the sale, the senior vice president now owns 66,439 shares of the company’s stock, valued at $4,113,902.88. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Tracy Marshbanks sold 64,221 shares of the firm’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $63.03, for a total value of $4,047,849.63. The disclosure for this sale can be found here. In the last three months, insiders sold 112,441 shares of company stock valued at $7,044,036. Corporate insiders own 31.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Nexthera Capital LP Acquires Shares of 41,905 ANI Pharmaceuticals Inc (ANIP)” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://ledgergazette.com/2018/03/13/nexthera-capital-lp-acquires-shares-of-41905-ani-pharmaceuticals-inc-anip.html.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.